antibody

Her2 Monoclonal Antibody

MBS9400271

0.05 mL

200 USD

monoclonal

mouse

nonconjugated

western blot, ELISA, immunohistochemistry, enzyme immunoassay

Antibody

Her2 Monoclonal Antibody

[Her2]

[C-erbB-2, EC 2.7.10.1, Epidermal growth factor receptor-related protein, ErbB2, HER2, MLN 19, NEU, NEU proto-oncogene, NGL, Receptor protein-tyrosine kinase erbB-2, Receptor protein-tyrosine kinase erbB-2 precursor, Tyrosine kinase-type cell surface recep]

[receptor tyrosine-protein kinase erbB-2 isoform b; Receptor tyrosine-protein kinase erbB-2; receptor tyrosine-protein kinase erbB-2; erb-b2 receptor tyrosine kinase 2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD_antigen: CD340]

[Her2]

[ERBB2; ERBB2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; HER2; MLN19; NEU; NGL; MLN 19]

ERBB2_HUMAN

Monoclonal

Mouse

Human

1225

Her2 antibody detects endogenous levels of total Her2

Affinity-chromatography

Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

1.0 mg/ml

Store at -20 degree C/1 year

ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC)

ELISA: 1:10000. WB: 1:500-1:2000. IHC: 1:200-1:1000

Western Blot (WB)

Immunogen Type: Recombinant protein. Immunogen Description: Purified recombinant fragment of human Her2 expressed in E. Coli

Target Name: Her2

Total protein Ab

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.

54792098

NP_001005862.1

NM_001005862.2

P04626

180KD

ARMS-mediated Activation Pathway (1269471); Adaptive Immune System Pathway (1269171); Adherens Junction Pathway (83070); Adherens Junction Pathway (481); Alpha6-Beta4 Integrin Signaling Pathway (198807); Axon Guidance Pathway (1270303); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Calcium Signaling Pathway (83050); Calcium Signaling Pathway (459)

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]

HER2: a proto-oncogenic receptor tyrosine kinase of the EGFR family. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. Not activated by EGF, TGF- alpha and amphiregulin. Amplified in breast cancer. Overexpression induces constitutive activity, and the gene is amplified or overexpressed in up to 30% of breast cancers, correlating with poor survival. The antibody Herceptin is approved for treatment of metastatic breast cancer with HER2 amplification/overexpression. Somatic mutations seen in 4% of lung cancers and also in breast, gastric, ovarian cancer and glioblastoma. One SNP shows predisposition to breast and gastric cancer. Inhibitors: Herceptin, lapatinib, PKI-166, EKB-569, CI-1033. Protein type: Kinase, protein; EC 2.7.10.1; Protein kinase, tyrosine (receptor); Protein kinase, TK; Membrane protein, integral; Oncoprotein; TK group; EGFR family. Chromosomal Location of Human Ortholog: 17q12. Cellular Component: perinuclear region of cytoplasm; basolateral plasma membrane; apical plasma membrane; cytoplasm; integral to membrane; plasma membrane; endosome membrane; cytoplasmic vesicle; nucleus; receptor complex. Molecular Function: protein C-terminus binding; protein dimerization activity; identical protein binding; protein binding; transmembrane receptor activity; ErbB-3 class receptor binding; protein heterodimerization activity; growth factor binding; protein-tyrosine kinase activity; transmembrane receptor protein tyrosine kinase activity; receptor signaling protein tyrosine kinase activity; protein phosphatase binding; ATP binding. Biological Process: myelination; axon guidance; phosphoinositide 3-kinase cascade; positive regulation of cell adhesion; peptidyl-tyrosine phosphorylation; positive regulation of translation; wound healing; nerve growth factor receptor signaling pathway; protein amino acid autophosphorylation; heart development; motor axon guidance; signal transduction; enzyme linked receptor protein signaling pathway; protein amino acid phosphorylation; positive regulation of transcription from RNA polymerase I promoter; positive regulation of MAP kinase activity; cell surface receptor linked signal transduction; oligodendrocyte differentiation; neuromuscular junction development; negative regulation of immature T cell proliferation in the thymus; epidermal growth factor receptor signaling pathway; regulation of microtubule-based process; fibroblast growth factor receptor signaling pathway; phosphoinositide-mediated signaling; transcription, DNA-dependent; positive regulation of cell growth; regulation of angiogenesis; peripheral nervous system development; cell proliferation; positive regulation of transcription from RNA polymerase III promoter; innate immune response; positive regulation of protein amino acid phosphorylation; positive regulation of epithelial cell proliferation; transmembrane receptor protein tyrosine kinase signaling pathway. Disease: Gastric Cancer; Lung Cancer; Glioma Susceptibility 1

0.05 mL

200 USD

0.1 mL

255